Elevai Labs, Inc. (ELAB)
| Market Cap | 31.68M |
| Revenue (ttm) | 1.03M |
| Net Income (ttm) | -3.08M |
| Shares Out | 17.33M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,818 |
| Open | 1.78 |
| Previous Close | 1.79 |
| Day's Range | 1.78 - 1.85 |
| 52-Week Range | 1.54 - 4.24 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 27, 2024 |
About ELAB
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California. [Read more]
Financial Performance
Financial StatementsNews
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
NEWPORT BEACH, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results for...
ELEVAI Labs, Inc. Expands International Distribution into Europe
NEWPORT BEACH, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB), a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partn...
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
NEWPORT BEACH, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signe...
Elevai Labs IPO Registration Document (S-1)
Elevai Labs has filed to go public with an IPO on the NASDAQ.